Clinical trials: Portopulmonary Hypertension
Portopulmonary Hypertension
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
This is an Open Label, Multicenter, pilot clinical trial to assess the efficacy and safety of an oral selective Endothelin Receptor Antagonist (ambrisentan) in patients with portopulmonary hypertension.
- Trial name
- Portopulm (NCT01224210)
- Testing
- Ambrisentan
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tufts Medical Center
Portopulmonary Hypertension
PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.
- Trial name
- PORTICO (NCT02382016)
- Testing
- Macitentan
- Where
- 52 sites in United States, Brazil and 5 more
- Volunteers
- 85 people
- Sponsor
- Actelion
Portopulmonary Hypertension, Pulmonary Hypertension
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means…
- Conditions
- Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
- Trial name
- NCT03309592
- Testing
- Ambrisentan Pill, Tadalafil Pill
- Where
- United States
- Sponsor
- Ochsner Health System
Portopulmonary Hypertension
Ambrisentan for Treatment of Portopulmonary Hypertension
Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension and is present in approximately 5% of cirrhotic patients.
- Trial name
- NCT01733095
- Testing
- ambrisentan
- Where
- Austria
- Sponsor
- Medical University of Graz
Portopulmonary Hypertension
Revatio Portal-Pulmonary Arterial Hypertension Trial
The investigators propose the first prospective, double blind, randomized controlled trial of treatment for pulmonary arterial hypertension (PAH) related to underlying portal hypertension.
- Trial name
- RePo1 (NCT01517854)
- Testing
- Sildenafil
- Where
- 3 sites in Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Portopulmonary Hypertension, Pulmonary Arterial Hypertension
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
This was a multicenter, prospective, observational, open-label study. Patients meeting inclusion/exclusion criteria received treatment with treprostinil as recommended by their treating physicians and were followed according to…
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- NCT01028651
- Testing
- Treprostinil
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Sildenafil and Pulmonary Artery Pressure
The purpose of the study is to see if the administration of sildenafil (Viagra) in patients with portopulmonary hypertension could be a safe and effective treatment.
- Trial name
- NCT00145938
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Chronic Liver Disease (CLD), Liver Cirrhosis
Heart Problems in Children With Chronic Liver Disease
Chronic liver disease (CLD) in children can sometimes lead to complications in other parts of the body, including the heart. The primary purpose of this observational study is to assess the presence and type of cardiac problems…
- Conditions
- Chronic Liver Disease (CLD), Liver Cirrhosis, Cardiac Abnormalities, Portopulmonary Hypertension
- Trial name
- NCT07502196
- Volunteers
- 60 people
- Sponsor
- Assiut University
Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH)
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation.
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH), Congenital Portosystemic Shunt
- Trial name
- Gen-PoPH-CPSS (NCT07314814)
- Testing
- targeted gene panels analysis, whole genome analysis
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Prof. Valérie Mc Lin